[1] Lehtonen LA, et al. Pharmacokinetics and pharmacodynamics of intravenous inotropic agents. Clin Pharmacokinet. 2004;43(3):187-203. DOI:
10.2165/00003088-200443030-00003[2] Erhardt L. An emerging role for calcium sensitisation in the treatment of heart failure. Expert Opin Investig Drugs. 2005 Jun;14(6):659-70. DOI:
10.1517/13543784.14.6.659[3] Yang G, et al. Effects of MCI-154 on vascular reactivity and its mechanisms after hemorrhagic shock in rats. J Cardiovasc Pharmacol. 2006;47(6):751-757. DOI:
10.1097/01.fjc.0000211790.14787.e7[4] Ming MJ, et al. Effects of MCI-154, a calcium sensitizer, on cardiac dysfunction in endotoxic shock in rabbits. Shock. 2000;13(6):459-463. DOI:
10.1097/00024382-200006000-00007